Swedish Orphan Biovitrum AB (publ) (BIOVF)
OTCMKTS
· Delayed Price · Currency is USD
30.48
+2.18 (7.70%)
At close: Jan 31, 2025
BIOVF Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 26,027 | 22,123 | 18,790 | 15,529 | 15,261 | Upgrade
|
| Revenue Growth (YoY) | 17.65% | 17.74% | 21.00% | 1.76% | 7.11% | Upgrade
|
| Cost of Revenue | 5,702 | 4,952 | 4,413 | 3,484 | 3,225 | Upgrade
|
| Gross Profit | 20,325 | 17,171 | 14,377 | 12,045 | 12,036 | Upgrade
|
| Selling, General & Admin | 10,960 | 9,773 | 7,637 | 6,294 | 5,981 | Upgrade
|
| Research & Development | 3,538 | 2,743 | 2,252 | 1,987 | 1,594 | Upgrade
|
| Other Operating Expenses | -6 | -9 | -32 | -30 | -2 | Upgrade
|
| Operating Expenses | 14,492 | 12,507 | 9,857 | 8,251 | 7,573 | Upgrade
|
| Operating Income | 5,833 | 4,664 | 4,520 | 3,794 | 4,463 | Upgrade
|
| Interest Expense | -1,219 | -1,111 | -458 | -419 | -454 | Upgrade
|
| Interest & Investment Income | - | 27 | 5 | - | 1 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -91 | -44 | 18 | -157 | Upgrade
|
| Other Non Operating Income (Expenses) | 1 | -49 | -27 | -35 | -33 | Upgrade
|
| EBT Excluding Unusual Items | 4,615 | 3,440 | 3,996 | 3,358 | 3,820 | Upgrade
|
| Merger & Restructuring Charges | -208 | -34 | -363 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -1 | - | -56 | -2 | Upgrade
|
| Asset Writedown | - | -65 | - | -7 | - | Upgrade
|
| Other Unusual Items | - | -385 | -312 | - | 399 | Upgrade
|
| Pretax Income | 4,407 | 2,955 | 3,321 | 3,295 | 4,217 | Upgrade
|
| Income Tax Expense | 528 | 546 | 683 | 616 | 972 | Upgrade
|
| Earnings From Continuing Operations | 3,879 | 2,409 | 2,638 | 2,679 | 3,245 | Upgrade
|
| Minority Interest in Earnings | 6 | - | - | - | - | Upgrade
|
| Net Income | 3,885 | 2,409 | 2,638 | 2,679 | 3,245 | Upgrade
|
| Net Income to Common | 3,885 | 2,409 | 2,638 | 2,679 | 3,245 | Upgrade
|
| Net Income Growth | 61.27% | -8.68% | -1.53% | -17.44% | -1.79% | Upgrade
|
| Shares Outstanding (Basic) | 342 | 323 | 296 | 295 | 295 | Upgrade
|
| Shares Outstanding (Diluted) | 346 | 326 | 298 | 297 | 298 | Upgrade
|
| Shares Change (YoY) | 6.01% | 9.22% | 0.56% | -0.28% | 1.06% | Upgrade
|
| EPS (Basic) | 11.37 | 7.47 | 8.92 | 9.08 | 11.01 | Upgrade
|
| EPS (Diluted) | 11.24 | 7.39 | 8.84 | 9.03 | 10.90 | Upgrade
|
| EPS Growth | 52.10% | -16.39% | -2.11% | -17.16% | -2.85% | Upgrade
|
| Free Cash Flow | 7,218 | 4,063 | 4,504 | 5,423 | 4,885 | Upgrade
|
| Free Cash Flow Per Share | 20.89 | 12.46 | 15.09 | 18.27 | 16.41 | Upgrade
|
| Gross Margin | 78.09% | 77.62% | 76.51% | 77.56% | 78.87% | Upgrade
|
| Operating Margin | 22.41% | 21.08% | 24.06% | 24.43% | 29.24% | Upgrade
|
| Profit Margin | 14.93% | 10.89% | 14.04% | 17.25% | 21.26% | Upgrade
|
| Free Cash Flow Margin | 27.73% | 18.37% | 23.97% | 34.92% | 32.01% | Upgrade
|
| EBITDA | 9,512 | 7,548 | 6,593 | 5,604 | 6,319 | Upgrade
|
| EBITDA Margin | 36.55% | 34.12% | 35.09% | 36.09% | 41.41% | Upgrade
|
| D&A For EBITDA | 3,679 | 2,884 | 2,073 | 1,810 | 1,856 | Upgrade
|
| EBIT | 5,833 | 4,664 | 4,520 | 3,794 | 4,463 | Upgrade
|
| EBIT Margin | 22.41% | 21.08% | 24.06% | 24.43% | 29.24% | Upgrade
|
| Effective Tax Rate | 11.98% | 18.48% | 20.57% | 18.69% | 23.05% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.